ToxStrategies consulting scientists provide a comprehensive range of services in nonclinical toxicology for the clinical development of biopharmaceutical (innovator and biosimilars) and pharmaceutical drug candidates. Our extensive experience with regulatory authorities, such as FDA, EMA, and Health Canada, enables us to successfully address scientific and regulatory hurdles throughout the drug approval process. We employ a product-specific approach to design nonclinical safety programs that are aligned with current regulatory expectations. Our overall strategy is to efficiently execute nonclinical studies that minimize costs and accelerate timelines for optimal success in clinical trials.
In these endeavors, ToxStrategies scientists provide consultation to our clients in areas that include:
Clinical Development Support
- Early discovery phase
- First-in-human Phase 1 clinical trials
- Phase 2/3
- Biologics Licensing Application (BLA), New Drug Application (NDA), Marketing Authorization Application (MAA)
- Registration and post-marketing
Biological Products
- Monoclonal antibodies
- Recombinant and fusion proteins
- Antibody/protein drug conjugates
- Bi-specific antibodies
- Biosimilars
- Enzyme replacement therapies
- Vaccines
Pharmaceutical Products
- Small molecules
- Botanicals
- Peptides
- Oligonucleotides
Disease Areas/Indications
- Oncology
- Pulmonary/allergy
- Metabolic
- Immunology, rheumatology
- Neurology
- Ophthalmology
- Anti-infectives
- Pediatric diseases
- Animal rule indications
- Orphan and rare diseases
Biopharmaceutical Expertise
- Selection of relevant animal species
- Immunogenicity or anti-drug antibodies
- Immunogenicity-mediated toxicity
- Cytokine-mediated toxicity
- Infusion reactions
Pharmacology/Toxicology Study Design and Protocol Development
- Species: mice, rats, rabbits, dogs, minipigs, and non-human primates
- Optimal study design for best science while minimizing cost
- General and mechanistic toxicology (in vitro and in vivo)
- Safety pharmacology
- Reproductive and developmental toxicology
- Carcinogenicity studies
- Tissue cross-reactivity
Management of GLP and Non-GLP Toxicology Studies
- Identify CROs and evaluate price bids
- Develop protocol
- Monitor study
- Manage day-to-day activities and issues
- Review/write study reports
- Address protocol deviations and study management issues
Comparability Studies
- Nonclinical studies to support manufacturing changes
- Risk-based strategy to support use of new material in clinical trials
- Biosimilars
- Changes in formulation or route of administration
Target Liability and Risk Assessment
- Evaluation of off-target or unexpected toxicity
- Metabolite safety qualification and assessment
- Generation of expert reports, white papers, and toxicology monographs
- Risk mitigation/management of toxicity
Regulatory Document Writing/ Preparation and Review
- PreIND
- IND, IMPD, and CTA
- EMA scientific advisory packages
- BLAs, NDAs, MAAs
- Investigator Brochures and clinical protocols
- Nonclinical expert reports (e.g., carcinogenicity risk assessment, waivers)
- Critical reviews and second opinions
Toxicology Representation
- Project Teams
- Board and venture capital (VC) funding meetings
- Regulatory authority meetings
- PreIND, EOP2, pre-BLA, pre-NDA, Advisory Committee meetings
- Type A, B, and C meetings (FDA)
- Biosimilar meetings
- EMA scientific advisory meetings
Regulatory Guidance and Strategy
- Provide current regulatory perspective
- Respond to regulatory authority and clinical investigator questions
- Address clinical holds associated with nonclinical toxicity
- Identify and mitigate nonclinical regulatory risks
Due Diligence Activities (In-licensing and Out-licensing)
- Data gap and target liability analyses
- Critical review of nonclinical programs for in-licensing
- Prepare summary of nonclinical package for out-licensing
For more information about ToxStrategies’ consulting services, please contact us.